• Lumos prioritizes top 100 urgent care groups, representing 40% of US sites
• Leading US urgent care group to deploy FebriDx across over 30 sites
• Three additional top 50 urgent care groups in clinical and economic validation

Lumos Diagnostics Holdings Ltd, a leader in rapid point-of-care diagnostic technologies, reports significant progress in its US commercialization strategy for FebriDx across its top 100 priority accounts. The company has adopted a four-stage commercial framework to track account progression from initial engagement to standardized adoption. A leading regional urgent care group has agreed to deploy FebriDx across over 30 sites, with an estimated 200,000 acute respiratory infection presentations annually. Additionally, three other top-tier urgent care groups are in clinical and economic validation, representing over 230 sites. These developments correspond to a potential 2.6 million ARI presentations annually, illustrating the scale of the addressable clinical opportunity.